Epizyme, Inc. (NASDAQ:EPZM)’s stock price was down 5.1% during mid-day trading on Wednesday . The company traded as low as $11.49 and last traded at $11.53. Approximately 752,186 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 833,861 shares. The stock had previously closed at $12.15.
Several research analysts recently weighed in on EPZM shares. Morgan Stanley dropped their price objective on shares of Epizyme from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Monday, November 9th. BidaskClub cut shares of Epizyme from a “hold” rating to a “sell” rating in a research report on Thursday, December 31st. Barclays dropped their price objective on shares of Epizyme from $33.00 to $18.00 and set an “overweight” rating for the company in a research report on Monday, November 9th. Finally, Jefferies Financial Group cut shares of Epizyme from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $18.00 to $14.00 in a research report on Monday, December 21st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $25.44.
The business’s fifty day simple moving average is $12.15 and its 200 day simple moving average is $12.87. The company has a current ratio of 8.95, a quick ratio of 8.71 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -5.17 and a beta of 1.82.
In other news, insider Shefali Agarwal sold 2,522 shares of the business’s stock in a transaction on Thursday, December 3rd. The shares were sold at an average price of $13.54, for a total value of $34,147.88. Following the completion of the transaction, the insider now owns 76,089 shares of the company’s stock, valued at approximately $1,030,245.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Carl Goldfischer purchased 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average cost of $12.07 per share, with a total value of $60,350.00. Following the acquisition, the director now directly owns 5,000 shares in the company, valued at $60,350. The disclosure for this purchase can be found here. 16.30% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in the company. North Star Investment Management Corp. grew its holdings in shares of Epizyme by 18.1% in the 4th quarter. North Star Investment Management Corp. now owns 139,800 shares of the biopharmaceutical company’s stock valued at $1,518,000 after buying an additional 21,400 shares during the period. Virtu Financial LLC acquired a new position in shares of Epizyme in the 3rd quarter valued at $231,000. MPM Oncology Impact Management LP grew its holdings in shares of Epizyme by 22.4% in the 3rd quarter. MPM Oncology Impact Management LP now owns 2,854,737 shares of the biopharmaceutical company’s stock valued at $34,057,000 after buying an additional 523,203 shares during the period. Paloma Partners Management Co bought a new stake in Epizyme in the 3rd quarter valued at $265,000. Finally, Twinbeech Capital LP bought a new stake in Epizyme in the 3rd quarter valued at $179,000. 89.43% of the stock is owned by institutional investors.
Epizyme Company Profile (NASDAQ:EPZM)
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States.
See Also: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.